Green LifeScience Co

Green LifeScience Co Equity

The The Equity of Green LifeScience Co (114450.KQ) as of Oct 22, 2026 is 38.29 B KRW. In the previous year, The Equity was 35.75 B KRW — a change of 7.11% (higher).

Equity

38.29 BKRW

YoY

7.11%

Last updated:

In 2025, Green LifeScience Co's equity was 38.29 B KRW, a 7.11% increase from the 35.75 B KRW equity in the previous year.

The Green LifeScience Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
59.11 B KRW
Jan 1, 2019
60.36 B KRW
Jan 1, 2020
59.37 B KRW
Jan 1, 2021
56.30 B KRW
Jan 1, 2022
52.64 B KRW
Jan 1, 2023
35.95 B KRW
Jan 1, 2024
35.75 B KRW
Jan 1, 2025
38.29 B KRW
The Green LifeScience Co Equity history
YEAREquityYoY
38.29 BKRW+7.11%
35.75 BKRW-0.57%
35.95 BKRW-31.70%
52.64 BKRW-6.50%
56.30 BKRW-5.18%
59.37 BKRW-1.63%
60.36 BKRW+2.11%
59.11 BKRW-4.80%
62.09 BKRW+0.70%
61.66 BKRW+8.38%
56.90 BKRW+10.42%
51.53 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Green LifeScience Co Stock analysis

What does Green LifeScience Co do? Green LifeScience Co Ltd produces and sells pharmaceutical and agricultural raw materials and intermediates, including AMZ for crop protection, TAZD as a herbicide intermediate, D003M and T003M for artificial marble additives, and PM04 as a pharmaceutical intermediate. The company distributes its products domestically and to international markets such as Japan, the United States, and Europe, where customers purchase these materials for agricultural and pharmaceutical applications. The firm also offers antibiotics as part of its product portfolio, targeting both domestic and overseas buyers seeking specialized chemical compounds. Green LifeScience Co Ltd generates revenue through the sale of its chemical products to customers in the agricultural and pharmaceutical sectors, with key markets including Japan, the United States, and European countries. The company’s product line caters to the needs of manufacturers requiring raw materials for crop protection, herbicides, and pharmaceutical production. Its domestic and international distribution channels support consistent sales across these segments, leveraging established relationships with buyers in the chemical supply chain. The company's offerings include specific chemical compounds like AMZ, TAZD, D003M, T003M, and PM04, which are sold to customers who integrate them into larger production processes. These products are used in the creation of crop protection materials, herbicides, artificial marble, and pharmaceuticals, serving both local and global markets. Antibiotics are also part of the sales mix, contributing to the firm’s revenue from chemical intermediates and raw materials. Green LifeScience Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Green LifeScience Co's Equity

Green LifeScience Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Green LifeScience Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Green LifeScience Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Green LifeScience Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Green LifeScience Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Green LifeScience Co stock

The Equity of Green LifeScience Co is 38.29 B KRW in 2025.

The Equity of Green LifeScience Co changed from 35.75 B KRW to 38.29 B KRW, representing a 7.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Green LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Green LifeScience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Green LifeScience Co

All Key Metrics — Green LifeScience Co